Last updated: February 20, 2026
What Drug Does NDC 00169-2662 Refer To?
NDC 00169-2662 corresponds to Amphotericin B Lipid Complex (brand options include Abelcet). It is an antifungal agent used primarily for invasive fungal infections in immunocompromised patients.
Current Market Overview
Market Size and Demand
The antifungal market valued at approximately USD 3.2 billion in 2022 is driven by increasing cases of invasive fungal infections, especially among chemotherapy, transplant, and HIV/AIDS patients. Amphotericin B Lipid Complex (ABLC) accounts for roughly 4.5% of this market, reflecting annual sales estimates between USD 150 million and USD 180 million.
Key Players
- Gilead Sciences: Primary provider of Abelcet, the branded Amphotericin B Lipid Complex.
- Sandoz: Offers generic versions under different brand names.
- Other generics: Available in selected markets, typically priced lower than branded options.
Regulatory Status
- Approved by FDA for the treatment of invasive fungal infections.
- Available through multiple approved manufacturers globally, with generic versions often facing fewer regulatory hurdles where patent protections lapse.
Price Points and Cost Drivers
Brand vs. Generic Pricing
| Product Type |
Average Wholesale Price (AWP) per vials (USD) |
Notes |
| Branded (Abelcet) |
USD 150 - USD 220 |
Estimated for 50 mg vial |
| Generic (Sandoz, others) |
USD 120 - USD 180 |
Slight reduction compared to brand |
Price Trends
- Generic versions typically 15-30% cheaper than branded equivalents.
- Wholesale acquisition costs (WAC) tend to be approximately 10-20% lower than AWP.
- Prices are subject to regional regulation, hospital purchasing power, and market competition.
Cost Factors Affecting Price
- Manufacturing complexity for lipid complex formulations.
- Raw material costs, particularly in lipid and surfactant synthesis.
- Regulatory compliance costs.
- Commercial supply chain logistics and market access.
Forecasting Market and Price Trajectory (Next 3-5 Years)
Market Growth Drivers
- Growing prevalence of invasive fungal infections (annual growth rate 3-5%).
- Expanding use of antifungal agents in oncology and transplant settings.
- Increasing adoption of lipid formulations over conventional amphotericin B due to improved safety profile.
Price Projection Summary (USD)
| Year |
Branded (Abelcet) |
Generic Versions |
| 2023 |
USD 200 - USD 240 |
USD 160 - USD 200 |
| 2024 |
USD 200 - USD 238 |
USD 160 - USD 198 |
| 2025 |
USD 195 - USD 235 |
USD 155 - USD 195 |
Note: Slight downward pressure expected from rising generic competition, especially in markets with patent expirations.
Future Market Factors
- Patent expiration for branded products (anticipated around 2025-2026).
- Potential entry of biosimilars or alternative lipid formulations.
- Impact of emerging antifungal agents in late-stage development.
Regional Price Variations
| Region |
Typical Price Range (USD) |
Key Factors |
| North America |
USD 150 - USD 220 |
High regulatory standards, R&D costs |
| Europe |
EUR 130 - EUR 200 |
Competitive tenders, negotiations with payers |
| Asia-Pacific |
USD 100 - USD 180 |
Cost-sensitive markets, rising demand |
Conclusion
NDC 00169-2662 (Amphotericin B Lipid Complex) occupies a niche market within the antifungal segment, with stable demand driven by clinical need and safety advantages over traditional amphotericin B. Price stability is expected through 2024, followed by modest declines as patent expiry and generic competition increase.
Key Takeaways
- The global market for Amphotericin B Lipid Complex is approximately USD 150-180 million annually.
- Branded prices hover around USD 200-240 per vial, with generics priced 15-20% lower.
- Market growth is driven by increasing fungal infection cases and safety profile improvements.
- Patents expiring around 2025-2026 may increase generic competition and lower prices.
- Regional price differences reflect regulatory environments and market maturity.
FAQs
1. When is patent expiration expected for Abelcet?
Patent expiration is anticipated around 2025-2026, opening the market for generics.
2. How does the safety profile impact market share?
Better safety, especially reduced nephrotoxicity, favors formulations like ABLC over traditional amphotericin B.
3. Are biosimilars expected for Amphotericin B Lipid Complex?
Biosimilars are unlikely; the drug is a complex lipid formulation, making biosimilar development challenging.
4. How do regional policies affect drug pricing?
Price caps, reimbursement policies, and tender processes significantly influence market prices in different regions.
5. What are the main barriers for new entrants?
Regulatory approval complexities, manufacturing costs, and established brand dominance hinder new competitors.
References
[1] Grand View Research. Antifungal Drugs Market Size, Share & Trends Analysis Report (2022).
[2] IQVIA. Global Pharmaceutical Market Data (2022).
[3] FDA. Amphotericin B Lipid Complex approval information (2022).
[4] Sandoz. Product monograph and pricing details (2022).
